A tobacco cessation referral pathway for community care
A tobacco cessation referral pathway between community pharmacies and primary care can convert a brief pharmacy contact into coordinated care. Tobacco use remains a major preventable cause of illness, and the Australian Institute of Health and Welfare reports that smoking contributes to more than 30 diseases. The 2022 ABS National Health Survey recorded 11.3% of adults as daily smokers. The 2021 Census showed daily smoking among 21.1% of Aboriginal and Torres Strait Islander people aged 15 and over, compared with 9.5% of non-Indigenous people, making culturally safe support a central design requirement.
Community pharmacies are well placed to reach people who do not attend a clinic. Everyday shopping can put tobacco and cessation support within the same few blocks: in Sydney, Melbourne and regional centres, supermarkets, convenience stores and tobacconists remain familiar tobacco outlets, while many community pharmacies share the same shopping strips. In rural and remote communities, the local pharmacy may be the most accessible health professional. Current Therapeutic Goods Administration rules require prescription-based pharmacy supply of nicotine vaping products and prohibit sales to people under 18, placing pharmacists at the centre of an evolving cessation market.
Why a referral pathway is needed
A referral pathway should answer four practical questions: when will a pharmacist offer support, what will be recorded, who receives the referral, and how will the patient know the next step. Without a shared process, good intentions can end with a brochure or a general recommendation to “see your doctor.” A written pathway makes the service consistent, reduces duplicated work and supports continuity when a patient moves between a pharmacy, a general practice and a quitline service.
The pharmacy team also needs time, privacy and a system that fits ordinary dispensing work. Workforce training on structured counselling, medication checks and follow-up can draw on community pharmacy medication management, where similar documentation and continuity principles apply. Management should agree a brief intervention that fits a standard consultation, then provide a private option for customers who do not want to discuss smoking at the counter. Clear escalation criteria matter when symptoms, medication changes or level of dependence exceed the pharmacist’s role.
Mapping the patient journey
The pathway can begin with an opt-in offer during medication counselling or when a customer purchases nicotine products. Using the 5As framework—Ask, Advise, Assess, Assist and Arrange follow-up—keeps the conversation focused. The pharmacist asks about current use, daily consumption, previous quit attempts, motivation and exposure to other tobacco or nicotine products. The assessment also considers relevant medicines, pregnancy, adolescent status, mental health conditions and whether the person wants help now.
Once consent is given, the agreed plan should specify treatment, referral destination and review time. For a customer ready to quit, the pharmacist can offer behavioural support and discuss nicotine replacement therapy, while a general practitioner can prescribe medicines when clinically appropriate and provide broader medical review. A patient who is ambivalent may receive brief advice, self-help resources and a planned follow-up. Consent should be revisited if the customer declines or changes their mind, and the record should distinguish advice from treatment actually supplied.
Delivering a brief cessation intervention
A useful pharmacy conversation combines empathy with clear action. Asking permission, such as “Would you like help to stop smoking?”, respects autonomy. Advice should be personalised rather than judgemental: connecting quitting to the customer’s own priorities can be more effective than delivering a standard lecture. Pharmacists can explain that combining a nicotine patch with short-acting gum or lozenge usually provides stronger relief than a single form, and that the first quit attempt is worth planning even if previous attempts failed.
Medication decisions require a safety review. Varenicline and bupropion are prescription medicines, and pharmacist prescribing authority varies between states and territories. A tobacco cessation service should therefore document who may prescribe, which shared-care arrangements apply and how a general practitioner is contacted. Reviewing all medicines is especially important because stopping smoking can change the handling of some drugs, including clozapine, olanzapine and warfarin. The pharmacist should use current guidance and refer for medical review where the regimen is complex.
Behavioural support should be offered alongside medicine. The national Quitline service on 13 QUIT (13 7848) provides coaching by phone, and some states offer additional phone, text and online support. Set a specific follow-up date rather than relying on the patient to return. A short check-in can confirm whether pharmacy treatment was started, whether the referral was received, whether side effects are present and whether the quit plan needs adjustment.
Creating a closed referral loop
A one-way referral leaves uncertainty for everyone. The referral should include the patient’s preferred name and contact details, consent, tobacco history, relevant clinical information, medication supplied, agreed actions and the date of review. The patient’s current general practitioner should be confirmed, while the patient may also choose a new practice if needed. Where urgent assessment is required, the pathway should direct the patient to emergency care rather than delay referral through a routine appointment.
Primary care should receive information that supports treatment rather than a pile of unfiltered records. At the appointment, the general practitioner can confirm dependence, review comorbidity and medicines, prescribe when needed and document the cessation plan. The general practice can send a response to the pharmacy through an agreed secure channel, such as secure messaging, fax or a patient-held summary. Digital systems should never be the only route, because some pharmacies or patients lack reliable connectivity or digital access.
The agreed feedback standard should specify who checks referrals, how quickly they are reviewed and what happens if the patient cannot be contacted. Non-attendance should trigger an offer of another appointment or alternate support, not closure of the episode. A named person in each service can maintain the process, while a broader clinical lead reviews exceptions. This matters in areas where staffing changes, after-hours cover and distance from services can interrupt continuity.
Using digital records and Quitline support
Digital tools can make the pathway visible without making digital access compulsory. A shared referral form can capture the minimum dataset and automatically route it to a general practice inbox, with the patient receiving a copy by SMS, email or print. The national 13 QUIT service can be included in the plan, while Healthdirect and local state quitline teams offer additional routes for people who prefer not to use a general practitioner. A telephone-based option remains essential for older customers, people with disability and remote communities.
Record sharing must remain consent-led. The Privacy Act 1988 and My Health Records Act 2012 shape how health information is handled, and practices should confirm what each service can lawfully store or transmit. Patients should know what is shared, with whom and for what purpose. A useful model is to offer a digital summary while retaining a paper or patient-held record. Staff also need a clear process for correcting information and escalating urgent concerns.
Teams can use professional pharmacy perspectives to frame the pathway as a clinical service rather than an optional promotional activity. Run-throughs should cover consent, cultural safety, privacy, medicine review, difficult conversations and failed referrals. Invite general practitioners, Aboriginal health practitioners, Quitline staff and consumers to test the form and workflow. Training in one location should not assume identical rules or resources in another, particularly across metropolitan, regional and remote areas.
Measuring performance and accountability
Measures should show whether patients receive support and whether that support leads to action. A monthly review can compare the number of tobacco-use questions asked with assessments completed, referrals accepted, Quitline connections and documented follow-ups. Process data should be interpreted with clinical supervision, because a low referral count may reflect poor record-keeping rather than low demand. Consumers should also be asked whether the service felt respectful, private and useful.
Process and experience measures
- Proportion of tobacco-use assessments with consent recorded
- Referrals sent to the patient’s confirmed general practice
- Patients given a Quitline number and a specific follow-up date
- Consumer feedback on privacy, respect and clarity
Clinical and system measures
- Proportion of referred patients receiving a documented response
- Self-reported smoking status at three-month follow-up
- Referral episodes completed, declined or redirected with a reason recorded
- Adverse effects, medication changes and urgent escalations documented
The comparison below defines ownership at each handover. The key standard is a named next action for every accepted referral, with feedback visible to both services. Use a small sample of records to test whether the form captures unnecessary information or omits anything needed for safe treatment.
| Pathway element | Community pharmacy | Primary care | Shared standard |
|---|---|---|---|
| Initial offer | Ask during appropriate consultations and offer private support | Ask during routine visits and chronic disease review | Consent recorded before screening or referral |
| Assessment | Record tobacco use, dependence, motivation and medicine safety | Confirm history, comorbidity, diagnosis and contraindications | A concise summary usable by the next clinician |
| Treatment | Provide agreed behavioural support and authorised pharmacy treatment | Prescribe and manage medicines when clinically appropriate | One documented quit plan and clear review date |
| Referral | Confirm destination and preferred contact method | Confirm receipt and contact patient or pharmacist | Feedback returned through an agreed secure channel |
| Follow-up | Review treatment use, side effects and referral completion | Review cessation progress and ongoing clinical needs | Escalation route for urgent or non-response |
Putting the pathway into practice
Start with a 90-day pilot led by one pharmacist, one general practitioner and a Quitline contact. Map the current route from first offer to follow-up, agree the minimum referral information and test the process with a handful of consenting patients. Review a sample of cases each month, including unsuccessful contacts and feedback from consumers. Keep ownership narrow, but make the expectations explicit: each referring service sends the information, each receiving service responds, and each patient receives a dated plan.
The immediate action is to place a signed service agreement beside the dispensing workflow and keep the referral form at the counselling bench. Include the local general practice, the state or territory Quitline, escalation contacts and the review date in one document. Train staff on the same script, publish the pathway for temporary staff and locums, and send the first referral this week.